You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Acute Myeloid Leukemia and the Role of FLT3 Inhibitors: Best Practices for the Interprofessional Care Team

  • Authors: Eunice S. Wang, MD; Alexander Perl, MD; Anthony Perissinotti, PharmD, BCOP
  • CME / ABIM MOC / CE Released: 1/30/2023
  • Valid for credit through: 1/30/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.75 ABIM MOC points

    Nurses - 0.75 ANCC Contact Hour(s) (0.75 contact hours are in the area of pharmacology)

    Pharmacists - 0.75 Knowledge-based ACPE (0.075 CEUs)

    IPCE - 0.75 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for community-based hematologists/oncologists, nurses, nurse practitioners, physician assistants, and pharmacists involved in the treatment of patients with AML.

The goal of this activity is for the AML care team to be better able to manage patients with FLT3-mutated AML, including diagnosis, prognosis, and treatment.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Prevalence and types of FLT3 mutations in AML
    • Clinical trial data evaluating the use of FLT3 inhibitors in patients with AML
  • Have greater competence related to
    • Collaborating with the interprofessional team to identify and manage treatment‐related adverse events in patients with AML who are receiving FLT3 inhibitors
  • Demonstrate greater confidence in their ability to
    • Selecting treatment based on FLT3 molecular testing results


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Eunice S. Wang, MD

    Chief of Leukemia and Benign Hematology Services
    Professor of Oncology
    Department of Medicine
    Roswell Park Comprehensive Cancer Center
    Buffalo, New York


    Eunice S. Wang, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; Amgen, Inc.; Astellas Pharma, Inc.; Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; Genentech; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen; Jazz Pharmaceuticals, Inc.; Kite Pharma, Inc.; Mana Therapeutics; Novartis; NuProbe; PharmaEssentia; Pfizer, Inc.; Stemline; Takeda
    Speaker or member of speakers bureau for: Stellas; Dava Oncology; Pfizer, Inc.; Stemline
    Research funding from: Amgen, Inc.; Aptevo; Arog; Cellectis; Gilead Sciences, Inc.; ImmunoGen, Inc.; Incyte Corporation; Loxo Oncology; Pfizer, Inc.; Stemline

  • Alexander Perl, MD

    Associate Professor, Department of Medicine
    Division of Hematology-Oncology
    Perelman School of Medicine at the University of Pennsylvania
    Attending Physician, Leukemia Program
    Abramson Cancer Center
    Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania


    Alexander Perl, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; Actinium; Astellas Pharma, Inc.; BerGenBio; Daiichi Sankyo, Inc.; Forma; Genentech; ImmunoGen, Inc.
    Research funding from: AbbVie, Inc.; Astellas Pharma, Inc.; Daiichi Sankyo, Inc.; FujiFilm; Syndax

  • Anthony Perissinotti, PharmD, BCOP

    Clinical Pharmacist Specialist, Hematology
    Clinical Team Leader, Hematology/Oncology Pharmacy
    University of Michigan
    Ann Arbor, Michigan


    Anthony Perissinotti, PharmD, BCOP, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; Aventis Pharmaceuticals, Inc.; BeiGene (Beijing) Co., Ltd; Janssen; Pfizer, Inc.; SERVIER


  • Lisa Cockrell, PhD

    Medical Education Director, Medscape, LLC


    Lisa Cockrell, PhD, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.75 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) (Universal Activity Number: JA0007105-0000-23-010-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Acute Myeloid Leukemia and the Role of FLT3 Inhibitors: Best Practices for the Interprofessional Care Team

Authors: Eunice S. Wang, MD; Alexander Perl, MD; Anthony Perissinotti, PharmD, BCOPFaculty and Disclosures

CME / ABIM MOC / CE Released: 1/30/2023

Valid for credit through: 1/30/2024


A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

  • Print